BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

198 related articles for article (PubMed ID: 37917529)

  • 1. Computational Prediction of Cyclic Peptide Structural Ensembles and Application to the Design of Keap1 Binders.
    Fonseca Lopez F; Miao J; Damjanovic J; Bischof L; Braun MB; Ling Y; Hartmann MD; Lin YS; Kritzer JA
    J Chem Inf Model; 2023 Nov; 63(21):6925-6937. PubMed ID: 37917529
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Recapitulating the Binding Affinity of Nrf2 for KEAP1 in a Cyclic Heptapeptide, Guided by NMR, X-ray Crystallography, and Machine Learning.
    Ortet PC; Muellers SN; Viarengo-Baker LA; Streu K; Szymczyna BR; Beeler AB; Allen KN; Whitty A
    J Am Chem Soc; 2021 Mar; 143(10):3779-3793. PubMed ID: 33683866
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cyclic Peptide Keap1-Nrf2 Protein-Protein Interaction Inhibitors: Design, Synthesis, and In Vivo Treatment of Acute Lung Injury.
    Zou J; Yan J; Lu Y; Yu Z; Zhang K; Han Q; Han D; Gai C; Chai X; Zhao Q; Zhuang C; Zou Y
    J Med Chem; 2024 Mar; 67(6):4889-4903. PubMed ID: 38485922
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A systematic molecular dynamics approach to the study of peptide Keap1-Nrf2 protein-protein interaction inhibitors and its application to p62 peptides.
    Lu MC; Yuan ZW; Jiang YL; Chen ZY; You QD; Jiang ZY
    Mol Biosyst; 2016 Apr; 12(4):1378-87. PubMed ID: 26935067
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Optimization of linear and cyclic peptide inhibitors of KEAP1-NRF2 protein-protein interaction.
    Colarusso S; De Simone D; Frattarelli T; Andreini M; Cerretani M; Missineo A; Moretti D; Tambone S; Kempf G; Augustin M; Steinbacher S; Munoz-Sanjuan I; Park L; Summa V; Tomei L; Bresciani A; Dominguez C; Toledo-Sherman L; Bianchi E
    Bioorg Med Chem; 2020 Nov; 28(21):115738. PubMed ID: 33065433
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Recent progress in Keap1-Nrf2 protein-protein interaction inhibitors.
    Mou Y; Wen S; Li YX; Gao XX; Zhang X; Jiang ZY
    Eur J Med Chem; 2020 Sep; 202():112532. PubMed ID: 32668381
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Discovery of a head-to-tail cyclic peptide as the Keap1-Nrf2 protein-protein interaction inhibitor with high cell potency.
    Lu MC; Jiao Q; Liu T; Tan SJ; Zhou HS; You QD; Jiang ZY
    Eur J Med Chem; 2018 Jan; 143():1578-1589. PubMed ID: 29117896
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Prediction of Binding Energy of Keap1 Interaction Motifs in the Nrf2 Antioxidant Pathway and Design of Potential High-Affinity Peptides.
    Karttunen M; Choy WY; Cino EA
    J Phys Chem B; 2018 Jun; 122(22):5851-5859. PubMed ID: 29745220
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Structural insights into the multiple binding modes of Dimethyl Fumarate (DMF) and its analogs to the Kelch domain of Keap1.
    Unni S; Deshmukh P; Krishnappa G; Kommu P; Padmanabhan B
    FEBS J; 2021 Mar; 288(5):1599-1613. PubMed ID: 32672401
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Monoacidic Inhibitors of the Kelch-like ECH-Associated Protein 1: Nuclear Factor Erythroid 2-Related Factor 2 (KEAP1:NRF2) Protein-Protein Interaction with High Cell Potency Identified by Fragment-Based Discovery.
    Davies TG; Wixted WE; Coyle JE; Griffiths-Jones C; Hearn K; McMenamin R; Norton D; Rich SJ; Richardson C; Saxty G; Willems HM; Woolford AJ; Cottom JE; Kou JP; Yonchuk JG; Feldser HG; Sanchez Y; Foley JP; Bolognese BJ; Logan G; Podolin PL; Yan H; Callahan JF; Heightman TD; Kerns JK
    J Med Chem; 2016 Apr; 59(8):3991-4006. PubMed ID: 27031670
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Nuclear factor (erythroid-derived 2)-like 2 (NRF2) drug discovery: Biochemical toolbox to develop NRF2 activators by reversible binding of Kelch-like ECH-associated protein 1 (KEAP1).
    Bresciani A; Missineo A; Gallo M; Cerretani M; Fezzardi P; Tomei L; Cicero DO; Altamura S; Santoprete A; Ingenito R; Bianchi E; Pacifici R; Dominguez C; Munoz-Sanjuan I; Harper S; Toledo-Sherman L; Park LC
    Arch Biochem Biophys; 2017 Oct; 631():31-41. PubMed ID: 28801166
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Development of a Cell-Permeable Cyclic Peptidyl Inhibitor against the Keap1-Nrf2 Interaction.
    Salim H; Song J; Sahni A; Pei D
    J Org Chem; 2020 Feb; 85(3):1416-1424. PubMed ID: 31609620
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Inhibiting the Keap1/Nrf2 Protein-Protein Interaction with Protein-Like Polymers.
    Carrow KP; Hamilton HL; Hopps MP; Li Y; Qiao B; Payne NC; Thompson MP; Zhang X; Magassa A; Fattah M; Agarwal S; Vincent MP; Buyanova M; Bertin PA; Mazitschek R; Olvera de la Cruz M; Johnson DA; Johnson JA; Gianneschi NC
    Adv Mater; 2024 May; 36(21):e2311467. PubMed ID: 38241649
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Emerging Substrate Proteins of Kelch-like ECH Associated Protein 1 (Keap1) and Potential Challenges for the Development of Small-Molecule Inhibitors of the Keap1-Nuclear Factor Erythroid 2-Related Factor 2 (Nrf2) Protein-Protein Interaction.
    Zhang Y; Shi Z; Zhou Y; Xiao Q; Wang H; Peng Y
    J Med Chem; 2020 Aug; 63(15):7986-8002. PubMed ID: 32233486
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Kelch-like ECH-associated protein 1 (KEAP1) differentially regulates nuclear factor erythroid-2-related factors 1 and 2 (NRF1 and NRF2).
    Tian W; Rojo de la Vega M; Schmidlin CJ; Ooi A; Zhang DD
    J Biol Chem; 2018 Feb; 293(6):2029-2040. PubMed ID: 29255090
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Molecular recognition between potential natural inhibitors of the Keap1-Nrf2 complex.
    Bello M; Morales-González JA
    Int J Biol Macromol; 2017 Dec; 105(Pt 1):981-992. PubMed ID: 28746889
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Structure-Activity and Structure-Conformation Relationships of Aryl Propionic Acid Inhibitors of the Kelch-like ECH-Associated Protein 1/Nuclear Factor Erythroid 2-Related Factor 2 (KEAP1/NRF2) Protein-Protein Interaction.
    Heightman TD; Callahan JF; Chiarparin E; Coyle JE; Griffiths-Jones C; Lakdawala AS; McMenamin R; Mortenson PN; Norton D; Peakman TM; Rich SJ; Richardson C; Rumsey WL; Sanchez Y; Saxty G; Willems HMG; Wolfe L; Woolford AJ; Wu Z; Yan H; Kerns JK; Davies TG
    J Med Chem; 2019 May; 62(9):4683-4702. PubMed ID: 30973731
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Structural and mechanistic insights into the Keap1-Nrf2 system as a route to drug discovery.
    Madden SK; Itzhaki LS
    Biochim Biophys Acta Proteins Proteom; 2020 Jul; 1868(7):140405. PubMed ID: 32120017
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Interaction Energetics and Druggability of the Protein-Protein Interaction between Kelch-like ECH-Associated Protein 1 (KEAP1) and Nuclear Factor Erythroid 2 Like 2 (Nrf2).
    Zhong M; Lynch A; Muellers SN; Jehle S; Luo L; Hall DR; Iwase R; Carolan JP; Egbert M; Wakefield A; Streu K; Harvey CM; Ortet PC; Kozakov D; Vajda S; Allen KN; Whitty A
    Biochemistry; 2020 Feb; 59(4):563-581. PubMed ID: 31851823
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Rational cyclization-based minimization of entropy penalty upon the binding of Nrf2-derived linear peptides to Keap1: A new strategy to improve therapeutic peptide activity against sepsis.
    Chen K; Huang L; Shen B
    Biophys Chem; 2019 Jan; 244():22-28. PubMed ID: 30465941
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.